CN105603073B - detection method of non-diagnosis purpose sputum microorganism drug resistance gene - Google Patents
detection method of non-diagnosis purpose sputum microorganism drug resistance gene Download PDFInfo
- Publication number
- CN105603073B CN105603073B CN201610060833.6A CN201610060833A CN105603073B CN 105603073 B CN105603073 B CN 105603073B CN 201610060833 A CN201610060833 A CN 201610060833A CN 105603073 B CN105603073 B CN 105603073B
- Authority
- CN
- China
- Prior art keywords
- gene
- sample
- genes
- drug
- drug resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a method for detecting drug resistance genes of non-diagnosis-purpose sputum microorganisms, which comprises the steps of determining drug resistance genes, endogenous standard genes and exogenous standard genes, preparing multiplex amplification primers, adding exogenous nucleic acid into a sample to be detected to obtain a mixed sample and extracting a genome, adding the exogenous standard genes into the genome to obtain the mixed nucleic acid, amplifying the mixed nucleic acid, constructing a high-throughput sequencing library by using an amplification product, performing high-throughput sequencing to obtain a sequencing fragment group, analyzing the sequencing fragment group, judging whether an experiment succeeds or not according to the obtained number of sequencing fragments of the exogenous standard genes and the endogenous standard genes, calculating the content of the drug resistance genes if the experiment succeeds, judging whether the sample to be detected contains the drug resistance genes or not according to the content of the drug resistance genes, and can quantitatively detect any multiple drug resistance genes to be detected in any microorganisms in a desired mode without culturing and purifying the microorganisms.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a detection method of non-diagnosis-purpose sputum microorganism drug resistance genes.
Background
The antibiotic is widely used in preventing and treating human diseases, and the abuse of antibiotic will cause the microbe to generate drug resistance gene and generate drug resistance, which makes the antibiotic ineffective in preventing and treating diseases.
The existing method for detecting drug-resistant genes comprises the steps of predicting pathogenic bacteria of drug-resistant genes to be detected carried on a sample to be detected, separating and purifying the pathogenic bacteria, amplifying the drug-resistant genes by PCR (polymerase Chain Reaction) primers, and judging whether the drug-resistant genes to be detected exist in the sample to be detected by times by utilizing an electrophoresis or real-time quantitative PCR method.
In the process of implementing the invention, the inventor finds that at least of the following problems exist in the prior art:
the method needs to culture, separate and purify pathogenic bacteria, so that the detection time is long, the treatment time is delayed, drug resistance genes in drug-resistant bacteria which cannot be cultured cannot be detected, times of detection can only aim at or a few pathogenic bacteria, times of detection can only detect or a few drug resistance genes, all the drug resistance genes in a sample to be detected cannot be detected, comprehensive information required by drug administration cannot be provided, and quantitative detection of the drug resistance genes cannot be realized.
Disclosure of Invention
In order to solve the problem that the method for detecting drug-resistant genes in the prior art needs to be improved, the embodiment of the invention provides methods for detecting drug-resistant genes of sputum microorganisms with non-diagnosis purposes, and the technical scheme is as follows:
the embodiment of the invention provides a detection method of non-diagnosis-purpose sputum microorganism drug resistance genes, which comprises the following steps:
determining drug resistance genes of microorganisms to be detected in a sample to be detected, endogenous standard genes in the sample to be detected and exogenous standard genes of the sample to be detected, wherein the sample to be detected is sputum;
preparing multiplex amplification primers for amplifying test regions of the drug resistance gene, the endogenous standard gene and the exogenous standard gene;
adding exogenous nucleic acid which cannot be amplified by the multiple amplification primers into the sample to be detected to obtain a mixed sample;
extracting the genome of the mixed sample;
adding the exogenous standard gene into the genome of the mixed sample to obtain mixed nucleic acid;
amplifying the mixed nucleic acid by using the multiple amplification primers to obtain an amplification product, and constructing a high-throughput sequencing library by using the amplification product;
performing high-throughput sequencing on the high-throughput sequencing library to obtain a sequencing fragment group;
analyzing the sequencing fragment group to obtain the number of the sequencing fragments of the drug resistance gene, the number of the sequencing fragments of the endogenous standard gene and the number of the sequencing fragments of the exogenous standard gene in the sample to be detected;
judging whether the experiment is successful or not according to the number of the sequencing fragments of the exogenous standard gene and the number of the sequencing fragments of the endogenous standard gene;
if the experiment is successful, calculating the content of the drug resistance gene in the sample to be tested;
and judging whether the sample to be detected contains the drug resistance gene or not according to the content of the drug resistance gene.
Specifically, the number of drug resistance genes is at least 1, the number of endogenous standard genes is at least 1, and the number of exogenous standard genes is at least 1.
Specifically, the endogenous standard gene is a gene in a microorganism of the sample to be tested.
Specifically, the exogenous standard gene is not present in an organism of known genome.
Specifically, the designed region or the amplified region of the primer for amplifying the drug-resistant gene has homology of less than 98% with the regions other than the drug-resistant gene on the genomes of all the organisms other than the regions of the genomes of the organisms in the test sample.
Specifically, the method for judging whether the experiment is successful or not comprises the steps of successfully performing the experiment when the number of the sequencing fragments of the exogenous standard gene and the number of the sequencing fragments of the endogenous standard gene are both more than or equal to α 1, and failing the experiment when the number of the sequencing fragments of the exogenous standard gene or the number of the sequencing fragments of the endogenous standard gene is less than α 1, wherein α 1 is a judgment threshold.
Specifically, the method for calculating the content of the drug resistance gene in the sample to be detected comprises the following steps: the content of the m-th drug resistance gene is calculated by the formula
Wherein i is the ith test region of the m-th drug resistance gene, n1 is the number of test regions of the m-th drug resistance gene, and bi is the numberThe number of sequencing fragments of the ith test region of the mth drug resistance gene, k is the kth endogenous standard gene, n3 is the number of endogenous standard genes, j is the jth test region of the kth endogenous standard gene, n2 is the number of test regions of the kth endogenous standard gene, and aj is the number of sequencing fragments of the jth test region of the kth endogenous standard gene; n is the total number of test regions for all of the endogenous standard genes.
Specifically, the method for judging whether the drug-resistant gene is contained in the sample to be detected comprises the steps of judging that the sample to be detected contains the drug-resistant gene when the content of the drug-resistant gene is not less than α 2, and judging that the sample to be detected does not contain the drug-resistant gene when the content of all the drug-resistant genes is less than α 2, wherein α 2 is a judgment threshold value.
Specifically, the ratio of the mass of the exogenous standard gene to the total mass of the genome of the mixed sample is greater than 1/100000.
The technical scheme provided by the embodiment of the invention has the advantages that the method provided by the embodiment of the invention can detect any multiple drug resistance genes to be detected in any number and types of microorganisms for times, quantitatively, quickly and accurately without culture and purification, and can give comprehensive information required by medication.
Detailed Description
To further clarify the objects, aspects and advantages of the present invention, a more detailed description of the embodiments of the present invention is provided in below.
Examples
Drug-resistant gene detection of human sputum microorganisms
The human sputum microorganisms reflect the types and the quantity of pathogenic microorganisms of various diseases of the human body, particularly respiratory diseases. Sputum samples used in this example were taken from coughing patients. The embodiment comprises the following steps:
step 1, determining drug resistance genes of microorganisms needing to be detected in a sample to be detected, endogenous standard genes in the sample to be detected and exogenous standard genes of the sample to be detected, wherein the specific method comprises the following steps:
wherein, the drug resistance genes are at least 1, the endogenous standard genes are at least 1, and the exogenous standard genes are at least 1. The endogenous standard gene is a gene in a microorganism of a sample to be tested. The foreign standard gene is not present in organisms of known genome.
The drug Resistance genes in this example are resistant to penicillin, β -lactamase, cephalosporinase, kanamycin and neomycin, wherein The drug Resistance genes APH (3') -Ia are resistant to kanamycin and neomycin simultaneously, The endogenous standard genes in this example are 1, specifically, The endogenous standard genes are ribosomal rRNA genes which are present in most organisms and have conserved regions, in this example, The exogenous standard genes are 1, specifically, The exogenous standard genes are ERCC-00004 genes, and when they are subjected to homologous alignment at NCBI (http:// www.ncbi.nlm.nih.gov), The presence of homologous sequences in The known organism reference genome is not found, i.e., The absence of The exogenous standard genes in The known organism genome is found, Table 1 is The information and detection results related to The genes to be detected in this example, and The name and sequence number of The drug Resistance genes in Table 1 are compared with The name and sequence number of The Antibiotic Resistance database (CRAD: The website of The recombinant Antibiotic Resistance gene/).
Table 1 shows the information and the results of the detection of the genes detected in this example
In Table 1, "/" indicates none.
Step 2, preparing a multiplex amplification primer for amplifying test areas of the drug resistance gene, the endogenous standard gene and the exogenous standard gene, wherein the specific method comprises the following steps:
specifically, the designed region of the primer for the drug resistant gene is conserved among different variants, thus ensuring that different variants of the same drug resistant gene can be amplified with the same primer, and if the designed region of the primer for the drug resistant gene has a homology of less than 98% with other regions of the genome of the organism in the sample to be tested, the primer will not amplify other regions, thus not interfering with the detection of the drug resistant gene, otherwise, the amplified region of the primer for the drug resistant gene is required to have a homology of less than 98% with other regions of the genome of the organism in the sample to be tested, thus obtaining an amplified product that can be distinguished from the drug resistant gene, also not interfering with the detection of the drug resistant gene, and at the same time, the amplification efficiency of each pair of primers in the multiplex amplification primers is between 95% and 105%.
Specifically, the sequences of the drug-resistant genes in table 1 are downloaded in an antibiotic resistance database, the numbering of the sequences of every downloaded drug-resistant genes is shown in table 1, a conserved region between different sequences of drug-resistant genes is obtained by utilizing homologous alignment and is used as a design region of a multiplex amplification primer, if the drug-resistant genes only contain sequences, the whole region of the sequence is used as the conserved region and the design region of the multiplex amplification primer, the design region of the multiplex amplification primer obtained in the above way is subjected to homologous alignment with other regions except the drug-resistant genes on the genome of all organisms through NCBI, and the design region of the multiplex amplification primer with homology lower than 98 percent is reserved, the V5 region of the ribosomal rRNA gene and the whole sequence of the exogenous standard gene ERCC-00004 are used as the conserved region and the design region of the multiplex amplification primer.
The procedure for obtaining the multiplex amplification primers is that the registration of multiplex PCR primers of Saimer Feishale company on-line design web pages https:// ampliseq. com/, the selection of DNA Hotspot designs (single-pool) "in" Application Type "option, the joining of the design regions of the obtained multiplex amplification primers with 100N, forming artificial reference genomes, and uploading the artificial reference genomes after the selection of" Custom "in" selection of the genome with use ", the selection of DNA Type option," DNA "selection, the random selection of more than 3 non-overlapping regions as amplification regions in the design region of the multiplex amplification primers, the filling of the regions into Add Hotspot option, the final click of" Subtargets "button submission, obtaining multiplex amplification primers for amplifying the endogenous Standard genes, the endogenous Standard genes and the exogenous Standard genes, the multiplex amplification primers of the genetic engineering (Shanghai), the multiplex amplification primers of the genes, the primer synthesis of the primers of the origin Standard, the sequence of the primers of the primer of the primers.
Step 3, adding exogenous nucleic acid which cannot be amplified by the multiple amplification primers into the sample to be detected, and extracting the exogenous nucleic acid and the genome of the sample to be detected to obtain a mixed sample, wherein the specific method comprises the following steps:
the method comprises the steps of adding exogenous nucleic acid into a sample to be detected, wherein the genome content of the sample to be detected is low, the genome extraction is difficult, the exogenous nucleic acid which cannot be amplified by a multiplex amplification primer needs to be added into the sample to be detected, the genome in the sample to be detected can be conveniently extracted, under the condition of , about 1ug of exogenous nucleic acid needs to be added, the normal extraction of the genome in the sample to be detected can be ensured, the amount of the added exogenous nucleic acid can be properly adjusted according to a nucleic acid extraction method, for example, the adding amount is increased during large-scale extraction, the adding amount can be properly reduced during ultramicro extraction, under the existing genome extraction technical level, is at least not less than 1 ng., the exogenous nucleic acid cannot be amplified by the multiplex amplification primer, therefore, the detection of a drug-resistant gene is not influenced, in the embodiment, the exogenous nucleic acid is ERCC-00024 gene, the sequence of the exogenous nucleic acid ERCC-00024 gene is shown in SEQ ID NO:13 in a sequence table, the ERCC-24 gene engineering (Shanghai) is discovered, the genome synthesis company, the genome synthesis is mixed with a limited sputum, and the sample can be extracted, and the normal sputum is obtained after the sample is mixed, the sputum is extracted, and the sample to be obtained.
Step 4, extracting the genome of the mixed sample, wherein the specific method comprises the following steps:
the genomic nucleic acid in the mixed sample is extracted according to the comparison of the extraction effect of different liquefaction methods (Zhang army, Tuo ya and Wang Yongmin (2009)) provided by Zhang army and the like on the extraction effect of the sputum DNA, namely, the test medicine 24(06): 456-. The amount of the genome of the obtained mixed sample was measured by using a double-stranded DNA program in a spectrophotometer (model Q5000, manufactured by Quawell, USA). In this example, the total amount of genome in the mixed sample was 1736 ng.
And 5, adding an exogenous standard gene into the genome of the mixed sample, wherein the ratio of the mass of the exogenous standard gene to the total mass of the genome of the mixed sample is more than 1/100000, and obtaining the mixed nucleic acid, wherein the specific method comprises the following steps:
in this example, the ratio of the mass of the foreign standard gene to the total mass of the genome of the mixed sample was 1/1000, and the total amount of the genome of the mixed sample was 1736ng, so 1.736ng of the foreign standard gene was added to obtain a mixed nucleic acid.
Step 6, amplifying the mixed nucleic acid by using the multiple amplification primers to obtain an amplification product, and constructing a high-throughput sequencing library by using the amplification product, wherein the specific method comprises the following steps:
the library construction kit 2.0 (manufactured by seimer feishel, usa, cat # 4475345) was used to construct a high-throughput sequencing library. The library construction kit comprises the following reagents: 5 × Ion AmpliSeqTMHiFi Mix, FuPa reagent, conversion reagent, sequencing linker solution, and DNA ligase. Method for constructing library according to operation manual of library construction kit IonAmpliSeqTMLibrary Preparation (publication number: MAN0006735, version: A.0). The multiplex PCR amplification system is as follows: 5 × Ion AmpliSeqTMHiFi Mix 4 ul, mixed liquid of prepared multiplex amplification primers 4 ul, mixed nucleic acid 10ng and enzyme-free water 11 ul. The amplification procedure for multiplex PCR was as follows: 99 ℃ for 2 minutes; (99 ℃, 15 seconds; 60 ℃, 4 minutes) x 25 cycles; keeping the temperature at 10 ℃. After redundant primers in the multiple PCR amplification product are digested by a FuPa reagent, phosphorylation is carried out, and the specific method comprises the following steps: adding 2 ul FuPa reagent into the amplification product of the multiplex PCR, mixing evenly, and reacting on a PCR instrument according to the following program: 10 minutes at 50 ℃; at 55 ℃ for 10 minutes; 10 minutes at 60 ℃; storing at 10 ℃ to obtain a mixture a, wherein the mixture a is a solution containing the phosphorylated amplification product. Connecting the phosphorylated amplification product with a sequencing adaptor by the following specific method: mu.l of the conversion reagent, 2. mu.l of the sequencing adapter solution and 2. mu.l of the DNA ligase were added to the mixture a, mixed and reacted on a PCR instrument according to the following procedure: 30 minutes at 22 ℃; 72 ℃ for 10 minutes; storing at 10 ℃ to obtain a mixed solution b. The mixture b was purified by standard ethanol precipitation and dissolved in 10. mu.l of enzyme-free water. Manufactured by Invitrigen corporation of America
And detecting the dsDNA HS Assay Kit (the product number is Q32852) according to the instruction, obtaining the mass concentration of the mixed solution b, and diluting the purified mixed solution b to 15ng/ml to obtain a high-throughput sequencing library with the concentration of about 100 pM.
And 7, performing high-throughput sequencing on the high-throughput sequencing library to obtain a sequencing fragment group, wherein the specific method comprises the following steps:
the obtained high-throughput sequencing library and a Kit Ion PI Template OT 2200 Kit v2 (manufactured by Invirrrigen, USA, with the product number of 4485146) are used for ePCR (Emulsion PCR) amplification before sequencing, and the operation method is carried out according to the operation manual of the Kit. High-throughput sequencing was performed on a Proton second generation high-throughput sequencer using the ePCR product and a Kit Ion PIsequencing 200Kit v2 (manufactured by Invirriggen, USA, Cat. No. 4485149), and the procedure was performed according to the manual of the Kit. In this example, the high throughput sequencing amount is set as 1M sequencing fragment (1M ═ 100 ten thousand), the sequencing length is set as 500 cycles, and after the sequencing is finished, the sequencing fragment group is obtained.
And 8, analyzing the sequencing fragment group to obtain the number of the sequencing fragments of the drug resistance gene, the number of the sequencing fragments of the endogenous standard gene and the number of the sequencing fragments of the exogenous standard gene in the sample to be detected, wherein the specific method comprises the following steps:
according to the primers of the sequencing fragments, blastall (version 2.2.26) software is utilized, according to default parameter settings, the sequencing fragment groups are compared to the detection areas of the drug resistance gene, the endogenous standard gene and the exogenous standard gene corresponding to the multiple amplification primers in the table 1, the sequencing fragments with homology higher than 98% with the detection areas (the sequencing fragments with homology lower than 98% may be obtained by non-specific amplification) are reserved, and respectively represent the number of the sequencing fragments of the drug resistance gene, the number of the sequencing fragments of the endogenous standard gene and the number of the sequencing fragments of the exogenous standard gene in a sample to be detected, and the results are shown in the table 1.
Step 9, judging whether the experiment is successful according to the number of the sequencing fragments of the exogenous standard genes and the number of the sequencing fragments of the endogenous standard genes, wherein the specific method comprises the following steps:
the method for judging whether the experiment is successful or not comprises the steps of judging whether the experiment is successful or not when the number of sequencing fragments of the exogenous standard genes and the number of sequencing fragments of the endogenous standard genes are both more than or equal to α 1, judging whether the experiment is successful or not when the number of sequencing fragments of the exogenous standard genes or the number of sequencing fragments of the endogenous standard genes is less than α 1, judging whether the experiment is failed or not, wherein α 1 is a judgment threshold value, if the number of the exogenous standard genes is too low, high-throughput library construction or high-throughput sequencing is possible, if the number of the endogenous standard genes is too low, nucleic acid extraction is possible, and if the experiment is unsuccessful, adjusting specific conditions until the experiment is successful, in the embodiment, α 1 takes 10 sequencing fragments, and as can be seen from table 1, the number of the sequencing fragments of the exogenous standard genes and the number of the sequencing fragments of the endogenous standard genes are both more than or not more than 10, so that the experiment provided by the embodiment.
Step 10, if the experiment is successful, calculating the content of the drug resistance gene in the sample to be tested, wherein the specific method comprises the following steps:
the content of the m drug resistance gene is calculated by the formula
Wherein i is the ith test region of the mth drug resistance gene, N1 is the number of the test regions of the mth drug resistance gene, bi is the number of sequencing fragments of the ith test region of the mth drug resistance gene, k is the kth endogenous standard gene, N3 is the number of endogenous standard genes, j is the jth test region of the kth endogenous standard gene, N2 is the number of the test regions of the kth endogenous standard gene, aj is the number of sequencing fragments of the jth test region of the kth endogenous standard gene, and N is the total number of the test regions of all endogenous standard genes.
As can be seen from table 1, in this example, 4 drug resistance genes were detected in total, so m is 4, and 1 test region was detected for each drug resistance genes, so N1 is 1, and 1 endogenous standard gene was detected in total, so N3 is 1, and 1 test region was detected for each endogenous standard gene, so N2 is 1, and N is 1, and table 1 lists the number of sequenced fragments for each drug resistance genes and endogenous standard genes, and substituting them into the calculation formula of the drug resistance gene content can obtain the drug resistance gene content of each genes, and the results are shown in table 1.
Step 11, judging whether the sample to be detected contains the drug resistance gene according to the content of the drug resistance gene, wherein the specific method comprises the following steps:
the method for determining that the sample to be tested contains the drug-resistant genes comprises the steps of determining that the sample to be tested contains the drug-resistant genes when the content of the drug-resistant genes is more than or equal to α, determining that the sample to be tested does not contain the drug-resistant genes when the content of all the drug-resistant genes is less than α, wherein α is a determination threshold α 2 is set artificially according to the required severity, and α is lower and higher when a small amount of the drug-resistant genes exists and the antibiotics are ineffective, and conversely, when the amount of the drug-resistant genes lacks and the effects of the antibiotics are the same, in most cases, α is set to 0.1% so as to balance between statistical errors and sensitivity, in the present example, α is set to 0.1%, as can be seen from table 1, in the present example, the content of all three drug-resistant genes except the drug-resistant gene cepS is more than or equal to α.1%, so that the sample to be determined as the drug-resistant genes containing the CTX-M-14, blaNDM-1 and APH (3') -corresponding to the antibiotic resistance genes, which are amplified by the primer , and the amplification effect of the multiple drug-resistant genes is expected to be detected on the basis of the multiple drug-resistant gene amplification of the patient, and the multiple drug-resistant gene amplification of the multiple-resistant gene amplification of the primer can be detected.
The detection result of this embodiment is verified, and the specific method is as follows:
synthesizing multiple amplification primers in the table 1 artificially, performing PCR amplification on DNA of a sample to be detected by using multiple amplification primers every multiple amplification primers, performing agarose electrophoresis detection on amplification products, finding that amplification bands exist in drug-resistant genes CTX-M-14, blaNDM-1 and APH (3') -Ia, judging the amplification bands to be positive if the amplification bands of both endogenous standard genes and exogenous standard genes are obvious, judging the amplification bands to be negative if the amplification products of the primers of cepS are not obvious, and judging the result to be equal to the detection result in the embodiment.
The method provided by the embodiment of the invention can detect different samples to be detected, has strong universality, sequencing is the ultimate standard of nucleic acid detection, so the detection result of the embodiment of the invention has high accuracy, and sequencing can distinguish single base difference, so the resolution of drug resistance gene detection of the embodiment of the invention is high.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (5)
1, A method for detecting resistance genes of non-diagnostic sputum microorganisms, the method comprising:
determining drug resistance genes of microorganisms to be detected in a sample to be detected, endogenous standard genes in the sample to be detected and exogenous standard genes of the sample to be detected, wherein the sample to be detected is sputum;
preparing multiplex amplification primers for amplifying test regions of the drug resistance gene, the endogenous standard gene and the exogenous standard gene;
adding exogenous nucleic acid which cannot be amplified by the multiple amplification primers into the sample to be detected to obtain a mixed sample;
extracting the genome of the mixed sample;
adding the exogenous standard gene into the genome of the mixed sample to obtain mixed nucleic acid;
amplifying the mixed nucleic acid by using the multiple amplification primers to obtain an amplification product, and constructing a high-throughput sequencing library by using the amplification product;
performing high-throughput sequencing on the high-throughput sequencing library to obtain a sequencing fragment group;
analyzing the sequencing fragment group to obtain the number of the sequencing fragments of the drug resistance gene, the number of the sequencing fragments of the endogenous standard gene and the number of the sequencing fragments of the exogenous standard gene in the sample to be detected, wherein the ratio of the mass of the exogenous standard gene to the total mass of the genome of the mixed sample is more than 1/100000;
judging whether the experiment succeeds or not according to the number of the sequencing fragments of the exogenous standard gene and the number of the sequencing fragments of the endogenous standard gene, wherein the method for judging whether the experiment succeeds or not is that when the number of the sequencing fragments of the exogenous standard gene and the number of the sequencing fragments of the endogenous standard gene are both more than or equal to α 1, the experiment succeeds, when the number of the sequencing fragments of the exogenous standard gene or the number of the sequencing fragments of the endogenous standard gene is less than α 1, the experiment fails, wherein α 1 is a judgment threshold value;
if the experiment is successful, calculating the content of the drug-resistant gene in the sample to be tested, wherein the method for calculating the content of the drug-resistant gene in the sample to be tested comprises the following steps: the content of the m-th drug resistance gene is calculated by the formula
Wherein i is the ith test region of the mth drug resistance gene, n1 is the number of the test regions of the mth drug resistance gene, bi is the number of the sequencing fragments of the ith test region of the mth drug resistance gene, k is the kth endogenous standard gene, n3 is the number of the endogenous standard genes, j is the jth test region of the kth endogenous standard gene, n2 is the number of the test regions of the kth endogenous standard gene, and aj is the number of the sequencing fragments of the jth test region of the kth endogenous standard gene; n is the total number of test regions of all the endogenous standard genes;
judging whether the sample to be detected contains a drug-resistant gene or not according to the content of the drug-resistant gene, wherein the method for judging whether the sample to be detected contains the drug-resistant gene is to judge that the sample to be detected contains the drug-resistant gene when the content of the drug-resistant gene is more than or equal to α 2, and judge that the sample to be detected does not contain the drug-resistant gene when the content of all the drug-resistant genes is less than α 2, wherein α 2 is a judgment threshold value.
2. The method of claim 1, wherein the number of drug resistance genes is at least 1, the number of endogenous standard genes is at least 1, and the number of exogenous standard genes is at least 1.
3. The method according to claim 1, wherein the endogenous standard gene is a gene in a microorganism of the sample to be tested.
4. The detection method according to claim 1, wherein the exogenous standard gene is not present in an organism having a known genome.
5. The method of claim 1, wherein the designed or amplified region of the primer for amplifying the drug resistance gene has less than 98% homology with other regions of the genome of the organism in the test sample.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610060833.6A CN105603073B (en) | 2016-01-29 | 2016-01-29 | detection method of non-diagnosis purpose sputum microorganism drug resistance gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610060833.6A CN105603073B (en) | 2016-01-29 | 2016-01-29 | detection method of non-diagnosis purpose sputum microorganism drug resistance gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105603073A CN105603073A (en) | 2016-05-25 |
| CN105603073B true CN105603073B (en) | 2020-01-31 |
Family
ID=55983408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610060833.6A Active CN105603073B (en) | 2016-01-29 | 2016-01-29 | detection method of non-diagnosis purpose sputum microorganism drug resistance gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105603073B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111394799A (en) * | 2020-03-11 | 2020-07-10 | 广州赛哲生物科技股份有限公司 | Method for constructing meningitis pathogen metagenome second-generation sequencing library and kit thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102181575A (en) * | 2011-03-18 | 2011-09-14 | 中国科学院武汉病毒研究所 | Primers and method for detecting drug resistance mutation site of hepatitis B virus |
| CN104561350A (en) * | 2015-01-28 | 2015-04-29 | 深圳华大基因研究院 | Kit and application thereof |
-
2016
- 2016-01-29 CN CN201610060833.6A patent/CN105603073B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102181575A (en) * | 2011-03-18 | 2011-09-14 | 中国科学院武汉病毒研究所 | Primers and method for detecting drug resistance mutation site of hepatitis B virus |
| CN104561350A (en) * | 2015-01-28 | 2015-04-29 | 深圳华大基因研究院 | Kit and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| Detection of cytomegalovirus drug resistance mutations by next-generation sequencing;Malaya K. Sahoo等;《Journal of Clinical Microbiology》;20131130;第51卷(第11期);3700-3710 * |
| 志贺菌1、2类整合子及ISCR1携带情况与耐药性的关系;董利娟等;《天津医药》;20150415;第63卷(第04期);400-403 * |
| 焦磷酸测序与PCR产物直接测序在乙型肝炎病毒耐药基因检测中的敏感性比较;孙树梅等;《中华医院感染学杂志》;20120720;第22卷(第14期);2991-2993 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105603073A (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boissinot et al. | The insertional history of an active family of L1 retrotransposons in humans | |
| CN106086013B (en) | A kind of probe and design method for nucleic acid enriching capture | |
| EP3730188B1 (en) | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases | |
| EP3218522B1 (en) | Detection methods based on sequencing | |
| CN110628890B (en) | Sequencing quality control standard product and application and product thereof | |
| CN107660234A (en) | The method of prediction organ-graft refection is sequenced using two generations | |
| CN111808854B (en) | Balanced joint with molecular bar code and method for quickly constructing transcriptome library | |
| EP2788506A2 (en) | Method and system for detection of an organism | |
| DK3105324T3 (en) | NGS SYSTEM CONTROL AND PROCEDURES COMPREHENSIVE THESE | |
| CN111690748B (en) | Probe set for detecting microsatellite instability by using high-throughput sequencing, kit and microsatellite instability detection method | |
| CN104093854A (en) | Method and kit for characterizing rna in a composition | |
| CN113564266A (en) | SNP typing genetic marker combination, detection kit and application | |
| CN105603073B (en) | detection method of non-diagnosis purpose sputum microorganism drug resistance gene | |
| CN106497916A (en) | A kind of construction method in the NK cell polygenic variations library for high-flux sequence detection and its application | |
| CN113840923A (en) | Methods, systems, and devices for nucleic acid detection | |
| CN116479103B (en) | Kit for detecting spinal muscular atrophy related genes | |
| Pichon et al. | Analysis and annotation of DNA methylation in two nonhuman primate species using the Infinium Human Methylation 450K and EPIC BeadChips | |
| CN105648060B (en) | Method for detecting drug-resistant genes of non-diagnostic human pathogenic microorganisms | |
| CN116497019A (en) | Transcription buffer solution capable of improving in-vitro synthesized RNA yield and transcription reaction system | |
| CN105603080B (en) | method for detecting drug-resistant genes of blood microbes for non-diagnosis purpose | |
| CN105586415B (en) | detection method of fecal microbe drug-resistant gene for non-diagnosis purpose | |
| CN109897822B (en) | Establishment and application of human immortalized B lymphocyte cell line | |
| CN105586410B (en) | Detection method of drug resistance genes of soil microorganisms | |
| CN105586417B (en) | Detection method of drug resistance genes of corn microorganisms | |
| CN105624297B (en) | Detection method of plant microorganism drug resistance gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |